RESPIRATORY SYNCYTIAL VIRUS (RSV)
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV) explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS (RSV) trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests an experimental mRNA vaccine called JCXH-108 for preventing respiratory syncytial virus (RSV) infection. About 75 healthy adults aged 18-45 or 60 and older will receive either the vaccine or a placebo. Researchers will monitor side effects and measure…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 01, 2026 19:27 UTC
-
New study to see if RSV shot for pregnant women shields newborns from severe illness
⭐️ VACCINE ⭐️ OngoingThis study looks at how well the RSVpreF vaccine (ABRYSVO) works when given during pregnancy to protect babies from severe RSV disease. Researchers will review health records of infants up to 12 months old who were hospitalized with breathing problems in Australia. No new treatme…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 30, 2026 15:51 UTC
-
Pregnant Women's RSV vaccine shields newborns, Real-World study shows
⭐️ VACCINE ⭐️ OngoingThis study checks how well the ABRYSVO vaccine works when given during pregnancy to protect babies from RSV, a common respiratory virus. Researchers will compare nearly 40,000 infants born to vaccinated and unvaccinated mothers, tracking infections and hospitalizations up to 24 m…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 30, 2026 15:50 UTC
-
Scientists dive deep into RSV vaccine immune response
Knowledge-focused OngoingThis study looks at how the immune system of adults aged 60 and older responds to the approved RSV vaccine. Researchers will measure antibodies and other immune markers in 14 participants over six months. The goal is to learn more about how the vaccine protects people, not to tes…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE4 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:50 UTC